Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
Lara, Beatriz
Lara, Beatriz
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2022-07
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Background: We aimed to evaluate the use of baricitinib, a Janus kinase (JAK) 1-2 inhibitor, for the treatment of patients admitted to hospital with COVID-19.
Citation
Lancet . 2022 Jul 30;400(10349):359-368
Type
Article